Illumina stock tanks as gene-sequencing company misses expectations and issues bleak outlook
Illumina Inc. shares sank 17% after hours Thursday after the gene-sequencing company swung to a loss in the second quarter, fell short of revenue expectations and revised its full-year outlook downward. Francis deSouza, chief executive of Illumina ILMN, +0.06%, said in a statement that the quarterly results failed to meet the company’s own expectations because … Read more